ADC Therapeutics to present at November investor conferences
CEO Ameet Mallik is scheduled to participate in upcoming healthcare industry events in Boston and London.
Lausanne-based ADC Therapeutics will participate in two upcoming investor conferences this November. CEO Ameet Mallik is slated to lead fireside chats at both events to discuss the company’s strategic outlook and ongoing developments in antibody drug conjugate (ADC) therapy.
The first engagement, the Guggenheim Third Annual Healthcare Innovation Conference, is scheduled for November 10 in Boston. Following this, Mallik will attend the Jefferies Global Healthcare Conference in London on November 19.
ADC Therapeutics, which focuses on oncology treatments, currently markets ZYNLONTA for the treatment of relapsed or refractory diffuse large B-cell lymphoma. These presentations provide a platform for the company to address its commercial performance and the status of its ongoing clinical research programs.